Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens
David Baden(University Hospital Schleswig-Holstein), Lars Fransecky, Sven Zukunft(University Hospital Carl Gustav Carus), Hermann Einsele(Universitätsklinikum Würzburg), Gerhard Ehninger(University Hospital Carl Gustav Carus), Markus Schaich(Rems-Murr-Klinikum), Gema Hernandez(TriNetX (United States)), Sebastian Scholl(Jena University Hospital), Alexander Kiani(Bayreuth Medical Center), Wolfgang E. Berdel(University Hospital Münster), Björn Steffen(Goethe University Frankfurt), Christoph Röllig(University Hospital Carl Gustav Carus), Martin Bornhäuser(Technische Universität Dresden), Carsten Müller‐Tidow(Heidelberg University), Alexander Pohlmann(University Hospital Münster), Claudia D. Baldus(University Hospital Schleswig-Holstein), Andreas Hochhaus(Jena University Hospital), Dirk Niemann(Gemeinschaftsklinikum Mittelrhein), Tim H. Brümmendorf(National University Cancer Institute, Singapore), Johannes Kullmer(DIAKO), Andreas Neubauer(RWTH Aachen University), Edgar Jost(Universitätsklinikum Aachen), Mathias Hänel(Klinikum Chemnitz), Nadine Wolgast(University Hospital Schleswig-Holstein), Christoph Schliemann(University Hospital Münster), Andreas Burchert(Philipps University of Marburg), Ulrich Kaiser(University of Applied Sciences Landshut), Maher Hanoun(Essen University Hospital), Uwe Platzbecker(National Center for Tumor Diseases), Stefan W. Krause(Universitätsklinikum Erlangen), Hubert Serve(Goethe University Frankfurt), Tim Sauer(Heidelberg University), Martin Kaufmann(Robert Bosch Hospital), Thomas Weber(University Hospital in Halle), Martin Görner(Klinikum Bielefeld), Wolfgang Blau(Universitätsklinikum Gießen und Marburg), Jan‐Henrik Mikesch(University Hospital Münster), Kerstin Schäfer‐Eckart(Nuremberg Hospital), Sophie Steinhäuser(University Hospital Schleswig-Holstein)
Cited by 13
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k